ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

CRMD CorMedix Inc

5,83
0,46 (8,57%)
Nach Börsenschluss
Zuletzt aktualisiert: 23:44:17
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
CorMedix Inc CRMD NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,46 8,57% 5,83 23:44:17
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
5,49 5,4305 5,92 5,84 5,37
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
19.4.202414:30GLOBECorMedix Inc. Announces CMS Grants TDAPA to DefenCath
15.4.202414:30GLOBECorMedix Inc. Announces U.S. Inpatient Commercial..
12.3.202412:30GLOBECorMedix Inc. Reports Fourth Quarter and Full Year 2023..
30.1.202423:26EDGAR2Form 8-K - Current report
18.1.202422:53EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
18.1.202402:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.1.202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.1.202402:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.1.202402:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202314:39EDGAR2Form 8-K - Current report
14.12.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.11.202322:11EDGAR2Form 8-K - Current report
14.11.202322:05GLOBECorMedix Inc. Reports Third Quarter and Nine Month 2023..
30.10.202321:35EDGAR2Form 8-K - Current report
11.10.202314:30GLOBECorMedix Inc. Announces Abstract Presentation at Upcoming..
13.9.202323:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13.9.202323:20EDGAR2Form DEF 14A - Other definitive proxy statements
08.9.202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.9.202314:30GLOBECorMedix Inc. Announces Publication of Phase 3 LOCK IT-100..
30.8.202314:00GLOBECorMedix Inc. Announces Issuance of U.S. Patent Covering..
17.8.202314:30EDGAR2Form 8-K - Current report
08.8.202314:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202313:45EDGAR2Form 8-K - Current report
08.8.202313:30GLOBECorMedix Inc. Reports Second Quarter and Six Month 2023..
30.6.202322:40EDGAR2Form 8-K - Current report
30.6.202322:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.6.202304:57GLOBECorMedix Inc. Announces Pricing of $40 Million Public..
28.6.202323:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28.6.202322:07GLOBECorMedix Inc. Announces Proposed Public Offering of Common..
21.6.202314:30GLOBECorMedix Inc. Announces FDA Acceptance of Resubmission of..
15.6.202314:30GLOBECormedix Inc. Announces Strategic Initiative With Boston..
16.5.202313:00GLOBECorMedix Inc. Announces Resubmission of New Drug Application..
15.5.202322:05GLOBECorMedix Inc. Reports First Quarter 2023 Financial Results..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock